Gamida Cell Ltd. (GMDA) Tops Q2 EPS by 67c

Gamida Cell Ltd. (NASDAQ: GMDA) reported Q2 EPS of $0.37, $0.67 better than the analyst estimate of ($0.30).

“The primary endpoint data for omidubicel underscore its potential to become an important treatment option for patients by providing a reliable graft source that can enable rapid neutrophil engraftment, which has been linked to other important outcomes such as fewer infections and hospitalizations,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. “We look forward to reporting secondary endpoints from the study and to initiating the biologics license application, or BLA, for omidubicel to the FDA on a rolling basis, both in the fourth quarter of this year.”

For earnings history and earnings-related data on Gamida Cell Ltd. (GMDA) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Z Squared outlines AI power strategy and Paradox Data acquisition